Patients with a prior history of squamous cell or basal carcinoma of the skin or in situ cervical cancer must have been curatively treated
Prior history of other malignancy except:\r\n* Basal cell carcinoma of skin\r\n* Cervical intra-epithelial neoplasia\r\n* Other cancer curatively treated with no evidence of disease for at least  years
History of other prior malignancy, except squamous cell carcinoma of the cervix or anus, superficial basal cell or squamous cell skin cancer, or other malignancy curatively treated more than  years ago before enrollment
Has a known additional malignancy that has progressed or required active treatment within the last  years with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers, and in-situ or intra-mucosal pharyngeal cancer
Has a known additional malignancy that is progressing or has required active treatment within the past  years with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers
Known additional malignancy within  years prior to enrollment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers
Active malignancy (other than BRAFv mutation-positive melanoma) or malignancy within  years prior to screening are excluded, with the exception of resected melanoma, resected basal cell carcinoma (BCC), resected cutaneous squamous cell carcinoma (SCC), resected carcinoma in situ of the cervix, resected carcinoma in situ of the breast, in situ prostate cancer, limited-stage bladder cancer, or any other curatively treated malignancies from which the participant has been disease-free for at least  years Ocular Exclusion Criteria:
Previous malignant disease other than breast cancer within the last  years, with the exception of basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or low-risk cancers considered curatively treated (i.e. complete remission achieved at least  years prior to first dose of study drugs and additional therapy not required while receiving study treatment).
Previous or concomitant cancers within the past  years other than curatively treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, curative treatment for transitional cell carcinoma of the bladder, and low risk prostate cancer; except for prostate cancer (which can be observed if low risk), other cancers listed must have been treated in the past  years without evidence of recurrence at the time of registration
Patients with a history of another primary malignancy within  years other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin
Concurrent malignancy or history of a previous malignancy within  year prior to first dose of the current study, unless curatively resected basal, squamous cell carcinoma of the skin, breast ductal/lobular carcinoma in situ or cervical carcinoma in situ
A history of other malignancy =<  years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or low risk/curatively treated prostate, thyroid, and cervical cancers
curatively treated cervical carcinoma in situ
Has a diagnosed additional malignancy within  years prior to first dose of trial treatment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin or curatively resected in situ breast cancers; subjects with another malignancy diagnosed >  years prior to the first dose of trial medication who were treated with curative intent and are not undergoing active therapy will be eligible
Patients diagnosed with additional malignancy within  years before the first OBP- administration with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cervical and/or breast cancers.
Previous malignant disease other than adenocarcinoma of the small intestine within the last  years, with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ considered curatively treated (i.e. complete remission achieved at least  years prior to first dose of avelumab AND additional therapy not required while receiving study treatment)
Prior malignancy (including invasive or ductal in-situ breast cancer) within  years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
Has a diagnosed additional malignancy within  years prior to first dose of study treatment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cervical and/or breast cancers
Has a diagnosed additional malignancy within  year prior to first dose of study treatment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cervical and/or breast cancers
Active or history of other malignancy other than the current cancer within  years of the first dose of ARQ , with the exception of carcinoma in-situ of the cervix, basal cell carcinoma, and superficial bladder tumors curatively treated
Prior malignancy, with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer, unless there is a -year disease-free interval
Disease free of prior malignancy for <  years with the exception of curatively treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, or transitional cell carcinoma
patients curatively treated for localized squamous or basal cell carcinoma of the skin or for carcinoma in situ of the uterine cervix (CIN) or breast,
History of prior malignancy within the last  years, with the exception of curatively treated basal or squamous cell carcinoma of the skin and low-grade in situ carcinoma of the cervix
Patients with a history of another primary malignancy within  years other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin
History of other malignancy within the last  years other than curatively treated basal and squamous cell carcinoma of the skin or carcinoma of the cervix in situ
Previous or concurrent malignancy with the following exceptions:\r\n* Adequately treated basal cell or squamous cell carcinoma of skin with adequate wound healing prior to study entry\r\n* In situ carcinoma of the cervix treated curatively and without evidence of recurrence\r\n* Primary malignancy completely resected and in complete remission >=  year
The patient has an active second malignancy other than curatively resected basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the bladder, or other cancers for which they are treated with curative intent with no active disease in the  years prior to enrollment.
Has a diagnosed additional malignancy within  years prior to first dose of study drug with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers.
Patients with a previous or current malignancy at other sites should be excluded, with the exception of:\r\n* Curatively treated local tumors such as carcinoma-in-situ of the cervix, basal or squamous cell carcinoma of the skin\r\n* Tumors for which no relapse has been observed within  years
Prior malignancy (including invasive or ductal in-situ breast cancer) within  years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.
Diagnosed and/or treated additional malignancy within  years of randomization, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin, and/or curatively-resected in situ cervical and/or breast carcinoma
Has a diagnosed additional malignancy within  years for Cohort  and  years for Cohort  prior to first dose of study treatment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cervical and/or breast cancers
Disease free of prior malignancy for <  years with the exception of curatively treated basal carcinoma of the skin or carcinoma in situ of the cervix
Previous or concomitant malignancy - EXCEPTIONS: patients with curatively treated carcinoma in situ of the cervix, basal cell of the skin, transitional cell carcinoma of the bladder, or early stage cancers at non-overlapping sites with no evidence of disease for >=  years
Diagnosed and/or treated additional malignancy within  years prior to randomization with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cervical and/or breast cancers
Previous or concurrent malignancy except adequately treated basal or squamous cell skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least  years
Diagnosed and/or treated additional malignancy within  years of randomization, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin, and/or curatively-resected in situ cervical and/or breast cancers
Prior breast or non-breast malignancy within  years prior to study entry, except for carcinoma in situ and basal cell and squamous cell carcinoma of the skin. Participants with malignancies occurring more than  years prior to study entry are permitted if curatively treated
patients curatively treated for localized squamous or basal cell carcinoma of the skin or for carcinoma in situ of the uterine cervix (CIN) or breast,
History of other active malignancy within  years prior to study entry with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively
History of prior other malignancy with the exception of curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study
Other malignancy within last  years except for the following: curatively treated basal cell/squamous cell skin cancer, carcinoma in situ of the cervix, superficial transitional cell bladder carcinoma, or in situ ductal carcinoma of the breast after complete resection
Patients with previous history of malignancy within the last  years except curatively treated squamous or basal cell carcinoma of the skin or curatively treated carcinoma in-situ of other organs
Prior malignancy within the past  years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, ductal carcinoma in situ of breast, in situ cervical carcinoma, and superficial bladder cancer
No previous or concurrent malignancy, other than curatively treated in situ squamous cell carcinoma of the cervix or basal cell carcinoma of the skin or non-active breast cancer
Prior malignancy(s) within the past  years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, locally advanced prostate cancer, ductal carcinoma in situ of breast, in situ cervical carcinoma and superficial bladder cancer
Disease free of prior malignancy for >=  years with the exception of curatively treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
Previous or concurrent malignancy with the following exceptions:\r\n* Carcinoma in situ\r\n* Adequately treated skin basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)\r\n* In situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least  years prior to the study\r\n* A primary malignancy which has been completely resected and in complete remission for >=  years
Any other current malignancy or previous malignancies within  years of enrollment except: curatively treated in situ carcinoma of the cervix uteri; localized basal or squamous cell carcinoma of the skin, curatively treated in situ breast carcinoma, and early stage prostate cancer
Any malignancy other than soft tissue sarcoma within the last  years prior to screening, with the exception of cervical carcinoma in situ, basal cell carcinoma, or superficial bladder tumors that have been successfully and curatively treated with no evidence of recurrent or residual disease.
Previous or concurrent malignancy with the following exceptions: \r\n* Adequately treated skin basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)\r\n* In situ carcinoma of the cervix, treated curatively and without evidence of recurrence\r\n* A primary malignancy which has been completely resected and in complete remission for >=  years
Curatively treated cervical carcinoma in situ.
The patient has an active second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers for which they are treated with curative intent, and no known active disease in the  years prior to enrollment.
Previous other malignancy within  years prior to the first dose of ARQ , with the exception of carcinoma in-situ of the cervix, basal cell carcinoma and superficial bladder tumors curatively treated.
No history of prior malignancy, with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer, unless there is a -year disease-free interval
Previous malignancy within  years prior to enrollment, except for curatively-treated basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, bladder carcinoma in situ or breast cancer in situ
History of non-breast malignancy within  years prior to randomization, except curatively treated superficial bladder cancer, carcinoma in situ of the cervix (stage -), and basal cell or squamous cell carcinoma of the skin
History of another active malignancy within  years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
